ClinicalTrials.gg
CompletedNCT06670573AR FHP AnxietyUpdated Nov 1, 2024

The Relationship Between Allergic Rhinitis, Forward Head Posture, and Anxiety Levels in Iranian Children

An observational study in Forward Head Posture and Allergic Rhinitis (Disorder), sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 7 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Hormozgan University of Medical Sciences · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
50
Ages
7 Years to 12 Years
Sex
All
01

Study summary

Forward head posture is a common postural issue across all age groups, often linked to the overuse of electronic devices such as computers, smartphones, and tablets, leading to poor posture in children. Allergic rhinitis is also prevalent in children, but its effects on musculoskeletal and psychological health are not well understood.

Objective: This study aimed to explore the relationship between allergic rhinitis, forward head posture, and anxiety levels in Iranian children aged 7-12 years.

Materials and Methods: Fifty children aged 7-12 were recruited from the Allergy-Infection Clinic at Bandar Abbas Children's Hospital. The participants were divided into two groups: 25 healthy children and 25 children diagnosed with allergic rhinitis. Anxiety levels were assessed using the Spence Anxiety Scale, while forward head posture was measured by analyzing photographs of the children's body profiles using AutoCAD software.

02

Conditions studied

  • Forward Head Posture
  • Allergic Rhinitis (Disorder)

Keywords

  • Allergic Rhinitis
  • Forward Head Posture
  • Anxiety
  • Children
03

In context

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

This study's enrollment of 50 is below the median of 120 across 143 observational studies indexed under Rhinitis, Allergic.

Browse Rhinitis, Allergic studies →

Lead sponsor

Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This is a randomized case- control that involved 50 children aged between 7 and 12 were enrolled in the Allergy-Infection Clinic at Bandar Abbas Children's Hospital, and the study took place between may to July 2024.

Eligibility criteria

The inclusion criteria :

  1. children to be between 7 to 12 years old,
  2. with and without Allergic Rhinitis,
  3. below 95%
  4. without asthma, cardiac diseases, neuromuscular diseases, tonsillectomy, congenital anomalies,
  5. using smart devices less than 3 hours.

The exclusion criteria :

1-no consent

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
50 participants (actual)
Patient registry
No

Groups and cohorts

  • 25 were healthy children

    25 were diagnosed with Allergic Rhinitis

06

What researchers measure

Primary outcomes

  1. Forward Head Posture

    Forward head posture (FHP) represents a common postural imbalance characterized by the positioning of the head in a forward orientation relative to the body's vertical axis

    Time frame: 2 month

07

Study locations

1 site
  • Tehran University
    Tehran, 7915893664, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Aug 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2024
First posted
Nov 1, 2024
StartActual
Jun 1, 2024
Primary completionActual
Aug 1, 2024
CompletionActual
Sep 18, 2024
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06670573
Lead sponsor
Hormozgan University of Medical Sciences
Collaborators
Tehran University
Responsible party
Mohammad Bagher Rahmati (Associate Professor, Hormozgan University of Medical Sciences) — Principal investigator
First posted
Nov 1, 2024
Start date
Jun 1, 2024
Primary completion
Aug 1, 2024
Completion
Sep 18, 2024
Last update
Nov 1, 2024

Study contacts

Hasan Daneshmandi, Professor
study director · Guilan University
Mohammad Hosein Alizade, Professor
study director · Tehran University
Mohammad Bagher Rahmati, Associate Professor
study director · Hormozgan University of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion